Company: RGNX
Filing Date: 2025-03-13
Form Type: POS AM
Source: 0001193125-25-053998
Chunk: 10

Company: REGENXBIO Inc.
Filing Date: 2025-03-13
Form: POS AM
Chunk 10
---
 of such date. Common Stock General Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of assets legally available at the times and in the amounts that our board of directors may determine from time to time. Upon our liquidation, dissolution or winding-up,the holders of common stock are entitled to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any outstanding preferred stock. Holders of common stock have no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to our common stock. Voting Rights Each holder of common stock is entitled to one vote per share on all matters submitted to a vote of stockholders. Notwithstanding the previous sentence, unless otherwise provided by law, holders of common stock are not entitled to vote on any amendment to our restated certificate of incorporation that relates solely to the terms of any preferred stock if the holders of such preferred stock are entitled to vote on such amendment. We have not provided for cumulative voting in the election of directors. The General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”), provides that holders of a class of stock will have the right to vote separately as a class on any proposal involving fundamental changes in the rights of the holders of that class of stock for proposals that adversely affect such holders. Stock Exchange Listing Our common stock is listed on The Nasdaq Global Select Market under the symbol “RGNX.” Transfer Agent and Registrar The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. 4

Pre-FundedWarrants As of December 31, 2024, we had outstanding 1,324,740 pre-fundedwarrants to purchase shares of our common stock at a price of $22.9999 per pre-fundedwarrant, which equaled the public offering price per share of our common stock in the registered public offering in which the warrants were issued, less the $0.0001 exercise price of each pre-fundedwarrant. The rights and privileges of the pre-fundedwarrants are set forth in the Warrant Agency Agreement, dated March 11, 2024, between the Company, Computershare Inc. and Computershare Trust Company, N.A., as warrant agent. The pre-fundedwarrants are exercisable at the option of the warrant holder at any time and do not expire. However, as set forth in the warrant agreements